Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | spike glycoprotein |
GTO ID | GTC3281 |
Trial ID | NCT05658523 |
Disease | COVID-19 |
Altered gene | S |
Therapeutic/Target gene | Therapeutic gene |
Therapy | mRNA vaccine |
Treatment | mRNA-1273|Elasomeran|Spikevax |
Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
Phase | Phase3 |
Recruitment status | Active, Not Recruiting |
Title | A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of a Bivalent mRNA Moderna COVID-19 Vaccine or a Protein-based Novavax COVID-19 Vaccine Given as a Fourth Dose in Healthy Adults in Australia |
Year | 2023 |
Country | Australia |
Company sponsor | Murdoch Childrens Research Institute |
Other ID(s) | 91108 |
Vector information | |||
|
Cohort1: mRNA-1273.214 | |||||||
|
|||||||
Cohort2: Novavax | |||||||
|
|||||||
Cohort3: no intervention | |||||||
|